Fasiglifam hemihydrate

Cat. No.: HY-W010655

CAS No.: 1374598-80-7

Molecular Formula: $C_{29}H_{33}O_{7.5}S$

Molecular Weight: 533.63

Target: Free Fatty Acid Receptor

Pathway: GPCR/G Protein

Storage: Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Fasiglifam (TAK-875) hemihydrate is a potent, selective and orally active GPR40 agonist with EC_{50} of 72 nM. Fasiglifam enhances glucose-dependent insulin secretion and improves hyperglycemia in type 2 diabetic rats. Fasiglifam can induce liver injury[1][2][3][4].
IC_{50} & Target	EC50: 72 nM (GPR40)[1]

CUSTOMER VALIDATION

- J Allergy Clin Immunol. 2018 Aug;142(2):470-484.e12.
- Proc Natl Acad Sci U S A. 2023 May 30;120(22):e2219569120.
- Biomed Pharmacother. 2023 May.
- Eur J Med Chem. 5 February 2022, 114061.
- J Cell Physiol. 2022 Jul 8.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Tsujihata Y,et al. TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats.J Pharmacol Exp

[2]. Yoshiyuki Tsujihata, et al. TAK-875, an Orally Available GPR40/FFA1 Agonist Enhances Glucose-Dependent Insulin Secretion and Improves Both Postprandial and Fasting Hyperglycemia in Type 2 Diabetic Rats. JPET July 13, 2011

[3]. Nagatake T, et al. 17,18-EpETE-GPR40 axis ameliorates contact hypersensitivity by inhibiting neutrophil mobility in mice and cynomolgus macaques. J Allergy Clin Immunol. 2017 Dec 26. pii: S0091-6749(17)32949-4.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA